Logo image of BEAM

BEAM THERAPEUTICS INC (BEAM) Stock Fundamental Analysis

USA - NASDAQ:BEAM - US07373V1052 - Common Stock

25.0324 USD
-0.86 (-3.31%)
Last: 10/7/2025, 1:30:02 PM
Fundamental Rating

3

Taking everything into account, BEAM scores 3 out of 10 in our fundamental rating. BEAM was compared to 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BEAM as it has an excellent financial health rating, but there are worries on the profitability. BEAM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BEAM has reported negative net income.
BEAM had a negative operating cash flow in the past year.
In the past 5 years BEAM always reported negative net income.
BEAM had negative operating cash flow in 4 of the past 5 years.
BEAM Yearly Net Income VS EBIT VS OCF VS FCFBEAM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M

1.2 Ratios

BEAM has a Return On Assets of -28.65%. This is in the better half of the industry: BEAM outperforms 68.47% of its industry peers.
BEAM's Return On Equity of -38.08% is fine compared to the rest of the industry. BEAM outperforms 73.32% of its industry peers.
Industry RankSector Rank
ROA -28.65%
ROE -38.08%
ROIC N/A
ROA(3y)-21.59%
ROA(5y)-26.65%
ROE(3y)-34.76%
ROE(5y)-45.77%
ROIC(3y)N/A
ROIC(5y)N/A
BEAM Yearly ROA, ROE, ROICBEAM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

BEAM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BEAM Yearly Profit, Operating, Gross MarginsBEAM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K

More info and screens

7

2. Health

2.1 Basic Checks

BEAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BEAM has been increased compared to 1 year ago.
The number of shares outstanding for BEAM has been increased compared to 5 years ago.
There is no outstanding debt for BEAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BEAM Yearly Shares OutstandingBEAM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
BEAM Yearly Total Debt VS Total AssetsBEAM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

An Altman-Z score of 2.62 indicates that BEAM is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of BEAM (2.62) is better than 67.16% of its industry peers.
There is no outstanding debt for BEAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.62
ROIC/WACCN/A
WACC9.53%
BEAM Yearly LT Debt VS Equity VS FCFBEAM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

BEAM has a Current Ratio of 6.75. This indicates that BEAM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.75, BEAM is in the better half of the industry, outperforming 67.72% of the companies in the same industry.
A Quick Ratio of 6.75 indicates that BEAM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.75, BEAM is in the better half of the industry, outperforming 67.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.75
Quick Ratio 6.75
BEAM Yearly Current Assets VS Current LiabilitesBEAM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for BEAM have decreased strongly by -148.62% in the last year.
BEAM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -82.90%.
Measured over the past years, BEAM shows a very strong growth in Revenue. The Revenue has been growing by 401.62% on average per year.
EPS 1Y (TTM)-148.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.91%
Revenue 1Y (TTM)-82.9%
Revenue growth 3Y7.01%
Revenue growth 5Y401.62%
Sales Q2Q%-28.08%

3.2 Future

BEAM is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.14% yearly.
The Revenue is expected to grow by 54.10% on average over the next years. This is a very strong growth
EPS Next Y3.44%
EPS Next 2Y0.72%
EPS Next 3Y-1.33%
EPS Next 5Y7.14%
Revenue Next Year-18.2%
Revenue Next 2Y-1.36%
Revenue Next 3Y4.27%
Revenue Next 5Y54.1%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BEAM Yearly Revenue VS EstimatesBEAM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
BEAM Yearly EPS VS EstimatesBEAM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BEAM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BEAM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BEAM Price Earnings VS Forward Price EarningsBEAM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BEAM Per share dataBEAM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.72%
EPS Next 3Y-1.33%

More info and screens

0

5. Dividend

5.1 Amount

BEAM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEAM THERAPEUTICS INC

NASDAQ:BEAM (10/7/2025, 1:30:02 PM)

25.0324

-0.86 (-3.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners105.17%
Inst Owner Change0%
Ins Owners1.21%
Ins Owner Change-0.13%
Market Cap2.53B
Analysts85.71
Price Target45.73 (82.68%)
Short Float %25.54%
Short Ratio9.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.45%
Min EPS beat(2)-0.76%
Max EPS beat(2)11.65%
EPS beat(4)3
Avg EPS beat(4)5.73%
Min EPS beat(4)-0.76%
Max EPS beat(4)11.65%
EPS beat(8)7
Avg EPS beat(8)40.33%
EPS beat(12)10
Avg EPS beat(12)32.9%
EPS beat(16)14
Avg EPS beat(16)30.03%
Revenue beat(2)0
Avg Revenue beat(2)-44.78%
Min Revenue beat(2)-50.74%
Max Revenue beat(2)-38.81%
Revenue beat(4)1
Avg Revenue beat(4)-4.74%
Min Revenue beat(4)-50.74%
Max Revenue beat(4)74.11%
Revenue beat(8)2
Avg Revenue beat(8)182.98%
Revenue beat(12)6
Avg Revenue beat(12)142.72%
Revenue beat(16)9
Avg Revenue beat(16)238.84%
PT rev (1m)-2%
PT rev (3m)1.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.08%
EPS NY rev (1m)1.27%
EPS NY rev (3m)6.32%
Revenue NQ rev (1m)-5.93%
Revenue NQ rev (3m)-16.46%
Revenue NY rev (1m)-6.74%
Revenue NY rev (3m)-19.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 42.01
P/FCF N/A
P/OCF N/A
P/B 2.42
P/tB 2.42
EV/EBITDA N/A
EPS(TTM)-4.5
EYN/A
EPS(NY)-4.51
Fwd EYN/A
FCF(TTM)-3.51
FCFYN/A
OCF(TTM)-3.41
OCFYN/A
SpS0.6
BVpS10.35
TBVpS10.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.65%
ROE -38.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.59%
ROA(5y)-26.65%
ROE(3y)-34.76%
ROE(5y)-45.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.89%
Cap/Sales 17.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.75
Quick Ratio 6.75
Altman-Z 2.62
F-Score3
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)185.1%
Cap/Depr(5y)305.75%
Cap/Sales(3y)34.46%
Cap/Sales(5y)16398.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-148.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.91%
EPS Next Y3.44%
EPS Next 2Y0.72%
EPS Next 3Y-1.33%
EPS Next 5Y7.14%
Revenue 1Y (TTM)-82.9%
Revenue growth 3Y7.01%
Revenue growth 5Y401.62%
Sales Q2Q%-28.08%
Revenue Next Year-18.2%
Revenue Next 2Y-1.36%
Revenue Next 3Y4.27%
Revenue Next 5Y54.1%
EBIT growth 1Y-141.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.51%
EBIT Next 3Y-6.86%
EBIT Next 5Y8.74%
FCF growth 1Y6.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.96%
OCF growth 3YN/A
OCF growth 5YN/A